2016
DOI: 10.1369/0022155416639013
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material

Abstract: Parallel studies of primary breast carcinomas and corresponding distant metastases samples reveal considerable differences. Our aim was to highlight this issue from another perspective and provide further data based on 98 patient samples: 69 primary breast carcinoma and 85 distant metastases from bone, central nervous system (CNS) and lung (56 paired). Two independent series of immunohistochemical reactions with different antibodies for estrogen receptor (ER), progesterone receptor (PgR) and human epidermal gr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
17
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(19 citation statements)
references
References 49 publications
2
17
0
Order By: Relevance
“…We and others have previously shown a substantial discordance rate between primary tumor and metastatic disease, with studies reporting hormone receptor discordance rates between 30% and 40% and HER-2/neu discordance rates between 10% and 30%. 1 , 3 , 4 , 8 10 Although the American College of Pathologists recommends biomarker analysis on primary and metastatic breast cancers, 13 to the authors’ knowledge this is the first report which analyzes the continued biomarker discordance of primary breast cancer with paired specimens of first and subsequent metastases. Our current study examined the markers on paired samples from subsequent sites of metastasis.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…We and others have previously shown a substantial discordance rate between primary tumor and metastatic disease, with studies reporting hormone receptor discordance rates between 30% and 40% and HER-2/neu discordance rates between 10% and 30%. 1 , 3 , 4 , 8 10 Although the American College of Pathologists recommends biomarker analysis on primary and metastatic breast cancers, 13 to the authors’ knowledge this is the first report which analyzes the continued biomarker discordance of primary breast cancer with paired specimens of first and subsequent metastases. Our current study examined the markers on paired samples from subsequent sites of metastasis.…”
Section: Discussionmentioning
confidence: 99%
“…Discordance between primary and metastatic breast cancer has been suggested for many years; however, most studies were retrospective, with only a few prospective studies now reporting biomarker discordance rates. 8 , 9 …”
Section: Discussionmentioning
confidence: 99%
“…morphology, tumor mutational burden, and eventually BRAF status [46,47]. At the time of the actual treatment, the latest information source is key to the optimal choice of therapy, thus, metastases shall be sampled and analyzed at time of progression [48,49]. Our study therefore further extends the existing knowledge on the role played by the BRAF V600E mutation in malignant melanoma.…”
Section: Discussionmentioning
confidence: 81%
“…An explanation to this may be the fact that metastatic tumors can change geno-or phenotype. Hence, different immunoprofiles of primary carcinomas and their metastasis may exist [15]. On the other hand, carcinomas of the unknown primary site represent, by themselves, a separate clinical entity that accounts for about 5% of all cancers [16].…”
Section: Discussionmentioning
confidence: 99%